CARBOGEN AMCIS opens new liquid drug product manufacturing facility
The Switzerland-based pharmaceutical process and ingredient developer and manufacturer announced the opening of their new sterile liquid drug product manufacturing facility in France.
Swiss API manufacturer and pharmaceutical process development company CARBOGEN AMCIS have officially opened their new state-of-the-art sterile liquid drug product manufacturing facility in Saint-Beauzire, France.
Construction of the facility began January 2021, and will be dedicated to custom development, manufacturing, and production of sterile injectable drugs and therapeutics. Through the new site, CARBOGEN AMICS’ capacity will also increase for product development and manufacturing of liquid and freeze-dried products for use in preclinical and clinical trials, as well as small-scale commercial use. The facility is located 7 km away from an existing CABOGEN AMCIS site in Riom.
With over 15 years of experience, the new CARBOGEN AMCIS facility will include two fully automated production lines for either liquid or freeze-dried drug products, with capacity to handle highly potent compounds and advance therapies, including antibody–drug conjugates. The company hopes to fill a need within the European pharmaceutical market for securing fill-finish capacity with flexible set-ups. The opening of this new facility will also create 50 new jobs throughout 2023, and employ approximately 100 highly skilled individuals. CARBOGEN AMCIS already operate nine sites across Europe, Switzerland, the UK, and China.
CEO of CARBOGEN AMCIS Pascal Villemagne commented on the opening: “Over the last 6 years, CARBOGEN AMCIS has continued to expand our facilities and grow our capacity, enabling us to support more customers and increase access to new and diverse technologies and services. Our new site will enable us to fully synergize our world-class chemistry skills and continue to bring our customers’ science to life, helping us play our part in the roll-out of new and better treatments, which help improve patients’ quality of life or treat otherwise terminal illness.”
Adding onto Villemagne’s comments, François Baduel, VP of Business Development, Sales, and Marketing of CARBOGEN AMCIS stated that “The opening of our new site in France signals an exciting time for us as we enhance our capacity to provide seamless drug product development and commercialisation services for leading pharmaceutical and biopharmaceutical companies on a global scale. Applying state-of-the-art containment technologies, our new site in France cements us as the partner of choice for [the] development and [manufacturing] of drug products.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance